

Publikace in extenso:

Články v časopisech s IF (IF 456)

- 1 Ludmila Muronova, Ondrej Soucek, David Zihala, Tereza Sevcikova, Tereza Popkova, Hana Plonkova, Ondrej Venglar, Ludek Pour, Martin Stork, Lucie Rihova, Renata Bezdekova, Jiri Minarik, Vojtech Látal, Martin Novak, Alexandra Jungova, Tereza Dekojova, Jan Straub, Martin Spacek, Vladimira Rezacova, Vladimír Maisnar, Jakub Radocha, Roman Hajek, Tomas Jelinek. Real-World Evidence on Prognostic Value of MRD in Multiple Myeloma Using Flow Cytometry. *Eur J Haematol.* 2025 Jan;114(1):155-163.
- 2 Mocikova H, Janikova A, Sykorova A, Prochazka V, Pirnos J, Duras J, Kopeckova K, Steinerova K, Pytlík R, Blahovcova P, Salek D, Kozak T, Bachanova V, Belada D. Outcome of patients with diffuse large B-cell lymphoma and testicular involvement - real world data. *Ann Hematol.* 2025 Jan;104(1):675-684.
- 3 Salmanton-García J, Marchesi F, Navrátil M, Piukovics K, Del Principe MI, Criscuolo M, Bilgin YM, Fracchiolla NS, Vena A, Romano A, Falces-Romero I, Sgherza N, Heras-Fernando I, Biernat MM, Petzer V, Žák P, Weinbergerová B, Samarkos M, Erben N, van Praet J, López-García A, Labrador J, Lahmer T, Drgoňa Ľ, Merelli M, Cuccaro A, Martín-Pérez S, Dávila-Valls J, Farina F, Cattaneo C, Pinczés LI, Magyari F, Espigado I, Buquicchio C, Vinh DC, Stoma I, Čerňan M, Prezioso L, Papa MV, Plantefève G, Khedr RA, Batinić J, Magliano G, Erdem S, Khostelidi S, Čolović N, Nappi D, García-Ramírez P, Góra J, Callejas-Charavia M, Tlustý J, Bakker M, Wojtyniak E, Antić D, Magdziak A, Dargenio M, Idrizović L, Pantić N, Stojanoski Z, Eisa N, Otašević V, Marchetti M, Mackenzie E, Garcia-Vidal C, Aujayeb A, Almasari A, Miranda-Castillo C, Gavriilaki E, Coppola N, Busca A, Adžić-Vukičević T, Schönlein M, Hersby DS, Gräfe SK, Glenthøj A, Aiello TF, Cvetanoski M, Mitrović M, Cerchione C, Prin R, Varricchio G, Arellano E, Córdoba R, Mayer J, Víšek B, Wolf D, Anastasopoulou AN, Delia M, Musto P, Leotta D, Bavastro M, Limongelli A, Sciumè M, van den Ven L, Fianchi L, Brunetti SC, Drozd-Sokołowska J, Dąbrowska-Iwanicka A, Cornely OA, Pagano L. Respiratory Viruses in Patients With Hematological Malignancy in Boreal Autumn/Winter 2023-2024: EPICOVIDEHA-EPIFLUEHA Report. *Am J Hematol.* 2025 Mar;100(3):358-374.
- 4 Musto P, Engelhardt M, van de Donk NWCJ, Gay F, Terpos E, Einsele H, Fernández de Larrea C, Sgherza N, Bolli N, Katodritou E, Gentile M, Royer B, Derudas D, Jelinek T, Zamagni E, Rosiñol L, Paiva B, Caers J, Kaiser M, Beksac M, Hájek R, Spencer A, Ludwig H, Cavo M, Bladé J, Moreau P, Mateos MV, San-Miguel JF, Dimopoulos MA, Boccadoro M, Sonneveld P. European Myeloma Network Group review and consensus statement on primary plasma cell leukemia. *Ann Oncol.* 2025 Apr;36(4):361-374.
- 5 Minarik J, Pour L, Latal V, Jelinek T, Straub J, Jungova A, Radocha J, Pavlicek P, Stork M, Pika T, Krhovska P, Popkova T, Sedlak F, Spicka I, Jindra P, Capounova V, Maisnar V, Hajek R. Lenalidomide based triplets in relapsed/refractory multiple myeloma: analysis of the Czech Myeloma Group. *BMC Cancer.* 2025 Apr 9;25(1):651.
- 6 Venglar O, Radova E, Zihala D, Tvrda I, Kubala V, Kutejova K, Muronova L, Kapustova V, Broskevicova L, Vrana J, Popkova T, Mihalyova J, Plonkova H, Sevcikova T, Kascak M, Navratil M, Koristek Z, Hajek R, Jelinek T. Level of Clonal Plasma Cells in Hematopoietic Cell Autografts Reflects the Pre-Transplant Bone Marrow Minimal Residual Disease in Multiple Myeloma Patients. *Am J Hematol.* 2025 Apr;100(4):704-707.
- 7 Jana Kotulová, Klára Baďurová, Zuzana Chyra, Sabina Ševčíková, Nikola Garbová, Tomáš Jelínek, Roman Hájek & Matouš Hrdinka. Novel immunotargets in multiple myeloma: biological relevance and therapeutic potential. *Biomark Res.* 2025 Jul 1;13(1):92.
- 8 Radim Dobiáš, Milan Navrátil, Rutuja H. Patil, Dominika Luptáková, David A. Stevens, and Vladimír Havlíček. Detection of Siderophores as a Superior Noninvasive Diagnostic Tool in Unraveling Mixed Fungal Infections. *ACS Omega* 2025 10 (21), 21908-21914.

- 9 Kapoor P, Dimopoulos MA, Ansell SM, Kastritis E, Advani R, Durot E, Morel P, Kyriakou C, Hajek R, Drandi D, Abeykoon JP, Chow S, Cao X, Patterson CJ, Matous JV, Buske C, Treon SP, Kersten MJ. Report of Consensus Panel 3 from the 12th International Workshop on Waldenström's Macroglobulinemia on the management of patients with high-risk disease. *Semin Hematol.* 2025 Apr;62(2):90-105.
- 10 Trněný M, Fogliato LM, Gardner F, Flinn IW, Larouche JF, Haioun C, Canales MA, Goto H, Hajek R, Salles GA, Singh A, Yan M, Kothari R, Man G, Sahin D, Hirata J, Lee C MD, Tilly H, Flowers CR. Analysis of peripheral neuropathy in the POLARIX study using clinician- and patient-reported outcomes. *Blood Adv.* 2025 Jul 8;9(13):3263-3267.
- 11 D'Sa S, Khwaja J, Chow S, Dimopoulos MA, Dogliotti I, Gatt ME, Hajek R, Lindsay J, Merlini G, Morel P, Tedeschi A, Cerchione C, Leiba M, Patterson CJ, Treon SP, Buske C, Matous JV, Varettoni M, Vos JMI, Eftimov F, Lunn MP, Kastritis E. Report of Consensus Panel 1 from the 12th International Workshop on the management of patients with IgM and Waldenström macroglobulinemia related neuropathy. *Semin Hematol.* 2025 Apr;62(2):76-84.
- 12 Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, Hájek R, Kim K, Grosicki S, Sia H, Bryant A, Pitombeira de Lacerda M, Martinez GA, Sureda Balarí A, Sandhu I, Cerchione C, Ganly P, Dimopoulos MA, Fu C, Garg M, Abdallah AO, Gatt ME, Oriol Rocafiguera A, Cavo M, Rifkin R, Fujisaki T, Mielnik M, Ficek J, Mantero A, Pirooz N, Varghese S, Lee J, McKeown A, Rogers R, Baig H, Eccersley L, Roy-Ghanta S, Mukhopadhyay P, Nielsen J, Opalinska J, Mateos MV; DREAMM-7 study investigators. Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial. *Lancet Oncol.* 2025 Aug;26(8):1067-1080.
- 13 Pánek T, Tice AK, Corre P, Hrubá P, Žihala D, Kamikawa R, Yazaki E, Shiratori T, Kume K, Hashimoto T, Ishida KI, Hradilová M, Silberman JD, Roger A, Inagaki Y, Eliáš M, Brown MW, Čepička I. An expanded phylogenomic analysis of Heterolobosea reveals the deep relationships, non-canonical genetic codes, and cryptic flagellate stages in the group. *Mol Phylogenet Evol.* 2025 Mar;204:108289.
- 14 Salek C, Hrabovsky S, Folber F, Koristek Z, Horacek JM, Fronkova E, Reznickova LR, Pecherkova P, Soukup P, Dluhosova B, Polivkova V, Krizkova J, Polakova KM, Vrzalova Z, Halamova H, Trka J, Cetkovsky P, Doubek M. Blinatumomab in induction therapy improves molecular response in untreated adults with Ph- B-cell precursor acute lymphoblastic leukemia. *Haematologica.* 2025 Jul 1;110(7):1644-1648.
- 15 Diamond B, Chahar D, Jain MD, Poos AM, Durante MA, Ziccheddu B, Kaddoura M, Papadimitriou M, Maclachlan KH, Jelinek T, Davies FE, Figura NB, Morgan GJ, Mai EK, Weisel K, Fenk R, Raab MS, Usmani S, Landgren O, Locke FL, Goldschmidt H, Schatz JH, Weinhold N, Maura F. Mutagenic impact and evolutionary influence of chemo-radiotherapy in hematologic malignancies. *Blood Cancer Discov.* 2025 Sep 3;6(5):450-463.
- 16 Dimopoulos MA, Terpos E, Boccadoro M, Moreau P, Mateos MV, Zweegman S, Cook G, Engelhardt M, Delforge M, Hajek R, Schjesvold F, Gay F, Manier S, Weisel KC, Kaiser M, van de Donk NWCJ, Zamagni E, Rodriguez-Otero P, Perrot A, Driessen C, Bila J, Laane E, Dytfeld D, Touzeau C, Beksac M, Raab MS, Cavo M, Mohty M, Spencer A, Ludwig H, Einsele H, San-Miguel J, Sonneveld P. EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma. *Nat Rev Clin Oncol.* 2025 Sep;22(9):680-700.
- 17 van de Donk NWCJ, Moreau P, San-Miguel JF, Mateos MV, Dimopoulos MA, Zweegman S, Gay F, Engelhardt M, Mina R, Zamagni E, Delforge M, Beksac M, Spencer A, Schjesvold F, Driessen C, Kaiser M, Perrot A, Wäsch R, Korst CL, Broijl A, Touzeau C, Manier S, Hajek R, Ludwig H, Fernandez de Larrea C, Popat R, Musto P, Rodriguez-Otero P, Yong K, Rasche L, Terpos E, Raab MS, Boccadoro M, Sonneveld P, Einsele H; EMN Guidelines Committee. Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma Network. *Lancet Haematol.* 2025 Aug;12(8):e635-e649.
- 18 Diamond BT, Baughn LB, Poorebrahim M, Poos AM, Lee H, Kaddoura M, Wiedmeier-Nutor JE, Durante MA, Otteson GE, Jevremovic D, Tang H, Fröhling S, Baertsch MA, Papadimitriou M, Ziccheddu B, Jelínek T, Lemoine C, Rak A, Green DJ, Landgren CO, Neri P, Bergsagel PL, Braggio E, Kumar SK, Raab MS, Fonseca R, Bahlis N, Weinhold N, Maura F. Biallelic antigen escape is a

- mechanism of resistance to anti-CD38 antibodies in multiple myeloma. *Blood*. 2025 Sep 25;146(13):1575-1585.
- 19 Martin Stork, Jakub Radocha, Jana Mihalyova, Ivan Spicka, Tomas Pika, Alexandra Jungova, Ivanna Boichuk, Klara Mensikova, Jan Straub, Frantisek Sedlak, Jiri Minarik, Petra Krhovska, Denisa Novakova, Michaela Hornakova, Zdenka Knechtova, Nela Sandlerova, Tereza Dekojova, Vladimir Maisnar, Tomas Jelinek, Roman Hajek, Ludek Pour. De-escalated Teclistamab dosing in relapsed/refractory multiple myeloma: Czech myeloma group real-world evidence analysis. *Ann Hematol*. 2025 Aug;104(8):4141-4147.
 - 20 Garces JJ, Diamond B, Sevcikova T, Nenarokov S, Bilek D, Radova E, Venglar O, Kapustova V, Firestone R, Maclachlan K, Simhal A, Broskevickova L, Vrana J, Muronova L, Popkova T, Mihalyova J, Plonkova H, Durante M, Ziccheddu B, Simicek M, Cho HJ, Mulligan G, Keats J, Zihala D, Landgren O, Hajek R, Usmani S, Maura F, Jelinek T. Elevated circulating tumor cells reflect high proliferation and genomic complexity in multiple myeloma. *Hemasphere*. 2025 Sep 23;9(9):e70218.
 - 21 Ronnacker J, Muller PJ, Mikesch JH, Zukunft S, Weinbergerová B, Šrámek J, Valka J, Novak J, Zak P, Sztokowski T, Koristek Z, Krekeler C, Unglaub JM, Sauer T, Ruhnke L, Kraus S, Schaffrath J, Müller LP, Kaes S, Niemann D, Fransecky L, Hess PP, Crysandt M, Jost E, Millo J, Gaertner J, Repp R, Jentzsch M, Hoppe L, Klein S, Modemann F, Michalowski N, Fischbach K, Blau W, Ruhs M, Ritter M, Lohmeyer J, Steffen B, Hauser S, Kaufmann M, Krause SW, Knabe R, Spiekermann K, Serve H, Platzbecker U, Baldus CD, Müller-Tidow C, Lenz G, Reinhardt HC, Mayer J, Bornhäuser M, Röllig C, Schliemann C, Hanoun M. Gemtuzumab ozogamicin in first-line treatment of CBF-AML: insights from a retrospective multi-center analysis. *Leukemia*. 2025 Sep;39(9):2174-2180.
 - 22 Dědečková K, Andrlík M, Móciková H, Kaliská L, Zapletalová S, Kubeš J, Al-Hamami S, Cutter DJ, Ntentas G, Vondráček V, Ondrová B, Marková J, Gahérová L, Mohammadová L, Procházka V, Michalka J, Sýkorová A, Ďuraš J, Kořen J, Navrátil M, Vařejková M, Doležal T, Prausová J; Czech Hodgkin Lymphoma Study Group. Proton beam therapy for mediastinal Hodgkin lymphoma: A prospective study of clinical efficacy and safety. *Radiother Oncol*. 2025 Jul;208:110931.
 - 23 Bolli N, D'Agostino M, Bagratuni T, Boccadoro M, Cavo M, Driessen C, Einsele H, Engelhardt M, Gay F, Gutiérrez NC, Hájek R, Holien T, João C, Kaiser M, Kortüm KM, Leypoldt L, Moreau P, Musto P, Ocio EM, Raab MS, Rasche L, Schjesvold F, Sevcikova T, Terpos E, Touzeau C, Van de Donk NWCJ, van Duin M, Weisel K, Zamagni E, Cupedo T, Sonneveld P, Terragna C. European Myeloma Network Group Consensus Statement on the use of next-generation sequencing for prognostic stratification of newly diagnosed multiple myeloma. *Hemasphere*. 2025 Oct 13;9(10):e70216.
 - 24 Venglar O, Radova E, Broskevickova L, Hajek R, Jelinek T. OMIP-117: 40-Parameter/37-Color Spectral Cytometry Panel for Robust Immunoprofiling of Human Lymphoid Subsets in Cancer Patients. *Cytometry A*. 2025 Oct;107(10):641-648
 - 25 Dluhošová B, Víšek B, Válka J, Čerňan M, Minařík L, Novák J, Šrámek J, Mertová J, Mertová J, Sztokowski T, Jonášová A, Karas M, Kořístek Z. Real-World Experience With Venetoclax-Based Therapy in Acute Myeloid Leukemia: Insights From the Czech Republic. *Clin Lymphoma Myeloma Leuk*. 2025 Jul 4:S2152-2650(25)00237-X.
 - 26 Gedeonová D, Bianchi C, Štembírek J, Hrdinka M, Chyra Z, Buchtová M, Hurník P, Blažek T, Režnarová J. BRCA1 and BRCA2 as prognostic markers in oral squamous cell carcinoma: a minireview. *Front Oncol*. 2025 Mar 28;15:1528822.
 - 27 Mateos MV, Trudel S, Quach H, Robak P, Beksac M, Pour L, Hus M, Kim K, Zherebtsova V, Delimpasi S, Jelínek T, Ward C, Ho PJ, Vorobyev VI, Lacerda MP, Martinez GA, Spicka I, Radocha J, Cavo M, Cerchione C, Fu C, Suzuki K, Rogers R, Phillips-Jones A, Wang Z, Baig H, Wilkes J, Zhou XL, Lewis E, Eccersley L, Sule N, Paka P, Opalinska JB, Mukhopadhyay P, Hungria VTM, Dimopoulos MA. Modification of Belantamab Mafodotin Dosing to Balance Efficacy and Tolerability in the DREAMM-7 and DREAMM-8 Trials. *Blood Adv*. 2025 Nov 25;9(22):5708-5719.
 - 28 Spencer A, Gavriatopoulou M, Coriu D, Lysén A, Gutierrez NC, Escalante F, Fantl D, Hajek R, Seguro F, Kaur G, Bittencourt RI, Bašić-Kinda S, Chu MP, Safah H, Martínez-López J, Crusoé EQ, De Farias DLC, Offidani M, Askari E, Sevindik OG, Maisnar V, Teng CJ, Hughes O, Taylor R, Lehn K, Feng D, Thiébaud-Millot R, Li X, Murray L, Jung P, Rossi EL, Kongpachith S, Nichol A, Ross JA, Hader C. Prospective real-world evaluation of t(11;14) prevalence and disease biology in multiple myeloma: MEDICI study analysis. *Blood Adv*. 2025 Nov 25;9(22):5814-5827.

- 29 Prokop Vodicka, Andrea Janikova, David Belada, Veronika Hanackova, Heidi Mocikova, Juraj Duras, Katerina Steinerova, Katerina Benesova, Eva Konirova, Tomas Prochazka, Kamila Polgarova, Michal Masar, Jitka Dlouha, Petra Blahovcova, Marek Trneny: Long-Term Real-World Outcomes of Primary CNS Lymphoma Patients Treated With MATRix Regimen Are Similar to IELSG32 Trial Results. *Hematol Oncol.* 2025 Nov;43(6):e70142.
- 30 Kateřina Dědečková, Michal Andrlik, Heidi Móciková, Lucia Kaliská, Simona Zapletalová, Jiří Kubeš, Sarah Al-Hamami, David J Cutter, Georgios Ntentas, Vladimír Vondráček, Barbora Ondrová, Jana Marková, Lúbia Gahérová, Lekaá Mohammadová, Vít Procházka, Jozef Michalka, Alice Sýkorová, Juraj Ďuraš, Jan Kořen, Matěj Navrátil, Michaela Vařejková, Tomáš Doležal, Jana Prausová; Czech Hodgkin Lymphoma Study Group. Proton beam therapy for mediastinal Hodgkin lymphoma: A prospective study of clinical efficacy and safety. *Radiother Oncol.* 2025 Jul;208:110931.
- 31 Hungria V, Hus M, Fu C, Zherebtsova V, Ward C, Ho PJ, Mikulski D, Muronova L, Cerchione C, Loubert A, Bunod L, M'Hari M, Pirooz N, Rogers R, Lin CP, Roy-Ghanta S, Opalinska JB, Purser M, McKeown A, McNamara S, Baig H, Eccersley L, Pompilus F, Mateos MV; DREAMM-7 trial study group. Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial. *Lancet Haematol.* 2025 Aug;12(8):e599-e610.
- 32 Niels W C J van de Donk, Philippe Moreau, Jesus F San-Miguel, Maria-Victoria Mateos, Meletios A Dimopoulos, Sonja Zweegman, Francesca Gay, Monika Engelhardt, Roberto Mina, Elena Zamagni, Michel Delforge, Meral Beksac, Andrew Spencer, Fredrik Schjesvold, Christoph Driessen, Martin Kaiser, Aurore Perrot, Ralph Wäsch, Charlotte L B M Korst, Annemiek Broijl, Cyrille Touzeau, Salomon Manier, Roman Hajek, Jelena Bila, Guldane C Seval, Michael O'Dwyer, Heinz Ludwig , Carlos Fernandez de Larrea, Rakesh Popat, Pellegrino Musto, Paula Rodriguez-Otero, Kwee Yong, Marin Kortüm, Leo Rasche, Evangelos Terpos, Marc S Raab, Mario Boccadoro, Pieter Sonneveld, Hermann Einsele; EMN Guidelines Committee. Sequencing BCMA- and GPRC5D-targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network. *Hemasphere.* 2025 Nov 25;9(11):e70260.
- 33 Jungova A, Stork M, Spicka I, Radocha J, Minarik J, Pavlicek P, Mihalyova J, Pour L, Straub J, Maisnar V, Pika T, Dekojova T, Soukup J, Popkova T, Mensikova K, Sedlák F, Pospiskova J, Boichuk I, Krhovska P, Stopka T, Jindra P, Jelínek T, Knechtová Z, Capounova V, Latal V, Muronova L, Heindorfer A, Ullrychova J, Sykora M, Kessler P, Hajek R. Treatment Patterns and Outcomes in Over 2200 Newly Diagnosed Multiple Myeloma Patients: Supporting Bortezomib-Lenalidomide-Dexamethasone as a Preferred Regimen in the Absence of Anti-CD38 Antibodies. *Clin Lymphoma Myeloma Leuk.* 2025 Nov 2:S2152-2650(25)04269-7.
- 34 Černý V, Pařízek A, Bláha J, Blatný J, Dulíček P, Gumulec J et al. Diagnosis and treatment of peripartum haemorrhage, consensus of the interdisciplinary working group by the modified ACCORD method. *Ceska gynekologie* 2025; 90(1): 72-89.
- 35 Szotkowski Tomáš, Čerňan Martin, Sopko Ladislav, Hrabovský Štěpán, Procházka Tomáš, Kořístek Zdeněk, Vydra Jan, Žibřidová Kateřina, Gálffy Balázs, Prchliková Adéla, Jindra Pavel, Ďuraš Juraj, Čemusová Barbora, Žák Pavel, Papajík Tomáš. A peripherally inserted central catheter offers a secure and reliable method of venous access for patients newly diagnosed with acute promyelocytic leukaemia. *J Vasc Access.* 2025 Jul 9:11297298251352693.
- 36 Bertamini L, Fokkema C, Rodriguez-Otero P, van Duin M, Terpos E, D'Agostino M, van der Velden VHJ, van de Donk NWJC, Delforge M, Driessen C, Hajek R, Einsele H, Vangsted AJ, Vieyra D, Attar RM, Sitthi-Amorn A, Carson R, Schjesvold F, Robak P, Beksac M, Spencer A, Broijl A, Cupedo T, Moreau P, Boccadoro M, Sonneveld P. Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone. *Blood.* 2026 Jan 22;147(4):431-442.
- 37 Tobias Deller, Jamal Alzubi, Laura Mosti, Marie Peschers, Christian Gratzke, Philipp Wolf, Toni Cathomen. Engineering of Humanized PSMA-directed CAR T Cells for Potent and Specific Elimination of Prostate Cancer Cells. *Cells.* 2025 Aug 28;14(17):1333.

- 38 Demel, I., Honová, S., Vaňková, K. et al. Overview of Pregnancy-Associated Thrombotic Microangiopathies – A Practical Guidance. Bratislava Medical Journal (2025) 126:3691–3708.

Články v recenzovaných a ostatních časopisech

- 1 Navrátil M, Úspěšná léčba sepse způsobené multirezistentní *Pseudomonas aeruginosa* pomocí cefiderokolu u hematologické imunokompromitované pacientky po alogenní transplantaci krvetvorby. *Klin.Onkol* 2025,38(3):209-212.
- 2 F. Folber; F. Benkó; B. Čemusová; J. Vydra; K. Polgárová; M. Trněný; B. Víšek; J. M. Horáček; J. Šrámek; P. Jindra; J. Mihályová; M. Kaščák; Z. Rusiňáková; A. Vranovský; M. Čerňan; T. Szotkowski; V. Řivnáčová; H. Móciková; J. Sýkora; T. Guman; D. Belada; M. Doubek; L. Drgoňa; P. Lesný. Guidelines for the management of adverse events following CD19 CAR-T cell therapy in adult patients with lymphomas and acute lymphoblastic leukemia: consensus of expert panel from certified centers in Czechia and Slovakia for 2025. *Transfuzie Hematol. dnes*,31, 2025, No. 4, p. 317-324.
- 3 B. Šušolová, J. Ďuraš, I. Kováčová, K. Hradská, M. Kaščák, M. Navrátil, M. Lachnit, R. Hájek, Výsledky 1. linie léčby non-Hodgkinových a Hodgkinových lymfomů v reálné praxi – analýza pacientů léčených na Klinice hematologie Fakultní nemocnice Ostrava v období od 2013 do 2022, *Transfuzie a hematologie dnes*. 2025, roč. 31, č. 2, s. 81-96.
- 4 Hájek R, Muroňová L, Mihályová J, Horňáková M, Popková T, Plonková H, Jelínek T. Nové terapeutické možnosti a trendy v léčbě mnohočetného myelomu. *Vnitr Lek*. 2025;71(3):176-182.
- 5 Drbohlavová E, Gumulec J, Bulikova A, Dulíček P, Hirmerová J, Malý R, Václavík J, Kessler P, Kacerovský M, Macek M, Calda P. Antitrombotické zajištění žen v průběhu těhotenství, kolem porodu a v šestinedělí, *Transfuzie Hematol. dnes*,31, 2025, No. 3, p. 199-204.
- 6 Ryšavá R, Koucký M, Šimetka O, Žák P, Bláha J, Frausová D, Indra T, Vojtěch J, Gumulec J. Doporučení pro diagnostiku a léčbu trombotických mikroangiopatií asociovaných s těhotenstvím a peripartálním obdobím – multidisciplinární konsenzus, *Transfuzie Hematol. dnes*,31, 2025, No. 3, p. 219-230.
- 7 Drbohlavová E, Gumulec J, Buliková A, Dulíček P, Hirmerová J, Malý R, Zápotocká E, Blatný J, Václavík J, Kessler P. Interdisciplinární doporučení pro testování trombofilie. *Transfuzie Hematol. dnes*,31, 2025, No. 2, p. 132-136.
- 8 Ďuraš J., Procházka V., Sýkorová A. Moderní terapeutické postupy v léčbě relabovaného a refrakterního lymfomu marginální zóny. *Transfuzie Hematol Dnes* 2025; 31(4): 1– 9.